Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRL-201 in R/R B-cell Lymphoma
NCT04213469Phase 1Completed
- Sponsor
- BRL Medicine Inc.
- Start
- Mar 2020
- Primary completion
- Nov 2021
- Modality
- Gene Silencing, CRISPR-Cas9, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BRL-201 in B cell lymphoma, sponsored by BRL Medicine Inc. Primary endpoints: Maximum Tolerated Dose at 28 days and Recommended Phase 2 Dose at 28 days. Started Mar 2020; status: completed.
02
Drugs
BRL-201
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT04213469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04213469.